Mason Bartels

Mason Bartels

Auto-generated profile, based on publicly available information

Mason Bartels

Baylor College of Medicine 2 Houston, Texas

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
Purpose: Cisplatin (CDDP)-based chemotherapy is a first-line treatment for patients with advanced head and neck squamous cell carcinomas (HNSCC), despite a high rate of treatment failures, acquired resistance, and subsequent aggressive behavior. The purpose of this study was to study the mechanism of CDDP resistance and metastasis in HNSCC. We investigated the role of NRF2 pathway activation as a driven event for tumor progression and metastasis of HNSCC. Experimental Design: Human HNSCC cell lines that are highly resistant to CDDP were generated. Clonogenic survival assays and a mouse model of oral cancer were used to examine the impact of NRF2 activation in vitro and in vivo on CDDP sensitivity and development of metastasis. Western blotting, immunostaining, whole-exome sequencing, single-cell transcriptomic and epigenomic profiling platforms were performed to dissect clonal evolution and molecular mechanisms. Results: Implantation of CDDP-resistant HNSCC cells into the tongues of nude mice resulted in a very high rate of distant metastases. The CDDP-resistant cells had significantly higher expression of NRF2 pathway genes in the presence of newly acquired KEAP1 mutations, or via epigenomic activation of target genes. Knockdown of NRF2 or restoration of the wild-type KEAP1 genes resensitized resistant cells to CDDP and decreased distant metastasis (DM). Finally, treatment with inhibitor of glutaminase-1, a NRF2 target gene, alleviated CDDP resistance. Conclusions: CDDP resistance and development of DM are associated with dysregulated and epigenetically reprogrammed KEAP1–NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP-resistant head and neck tumors.


25 November 2025
Verified
Other
Open access
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
Cisplatin sensitivity following knockdown of NRF2 or restoration of wildtype KEAP1 in cisplatin resistant HNSCC cells is not mediated through apoptosis.

25 November 2025
Verified
Other
Open access
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
In vivo expression of cisplatin transporters in CDDP resistant HNSCC tumors.

25 November 2025
Verified
Other
Open access
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
Whole exome sequencing showing mutational status in the parental HN30-P versus HN30-R8 cisplatin resistant cell lines.

3 April 2023
Verified
Other
Open access
AOAbdullah A. Osman
Abdullah A. Osman
EAEmre Arslan
Emre Arslan
MBMason Bartels
Mason Bartels
CMChieko Michikawa
Chieko Michikawa
ALAntje Lindemann
Antje Lindemann
JMJeffrey Myers
Jeffrey Myers
Purpose:Cisplatin (CDDP)-based chemotherapy is a first-line treatment for patients with advanced head and neck squamous cell carcinomas (HNSCC), despite a high rate of treatment failures, acquired resistance, and subsequent aggressive behavior. The purpose of this study was to study the mechanism of CDDP resistance and metastasis in HNSCC. We investigated the role of NRF2 pathway activation as a driven event for tumor progression and metastasis of HNSCC.Experimental Design:Human HNSCC cell lines that are highly resistant to CDDP were generated. Clonogenic survival assays and a mouse model of oral cancer were used to examine the impact of NRF2 activation in vitro and in vivo on CDDP sensitivity and development of metastasis. Western blotting, immunostaining, whole-exome sequencing, single-cell transcriptomic and epigenomic profiling platforms were performed to dissect clonal evolution and molecular mechanisms.Results:Implantation of CDDP-resistant HNSCC cells into the tongues of nude mice resulted in a very high rate of distant metastases. The CDDP-resistant cells had significantly higher expression of NRF2 pathway genes in the presence of newly acquired KEAP1 mutations, or via epigenomic activation of target genes. Knockdown of NRF2 or restoration of the wild-type KEAP1 genes resensitized resistant cells to CDDP and decreased distant metastasis (DM). Finally, treatment with inhibitor of glutaminase-1, a NRF2 target gene, alleviated CDDP resistance.Conclusions:CDDP resistance and development of DM are associated with dysregulated and epigenetically reprogrammed KEAP1–NRF2 signaling pathway. A strategy targeting KEAP1/NRF2 pathway or glutamine metabolism deserves further clinical investigation in patients with CDDP-resistant head and neck tumors.